Loading...
•
Sep 30, 2020
OrthoPediatrics Q3 2020 Earnings Report
OrthoPediatrics demonstrated revenue growth and improved EBITDA, achieving positive adjusted EBITDA.
Key Takeaways
OrthoPediatrics Corp. reported a 7.0% increase in total revenue for Q3 2020, reaching $22.2 million, driven by a 16.7% growth in U.S. revenue. The company also achieved positive adjusted EBITDA, reflecting strong gross margin and cost control.
Total revenue increased by 7.0% to $22.2 million compared to Q3 2019.
U.S. revenue grew by 16.7% compared to the same period last year.
Adjusted EBITDA was positive during the quarter.
Orthex execution continued strongly, with a 167% increase in first-time users year-to-date.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Revenue by Segment
Trauma & Deformity Revenue
CapyFin.comScoliosis Revenue
CapyFin.comSports Medicine/Other Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company expects overall sales growth during the fourth quarter 2020 to be similar to the third quarter. Fourth quarter sales growth in the U.S. is expected to accelerate slightly, while the international sales decline in the fourth quarter should be similar to the third quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income